» Articles » PMID: 30592675

Haematopoietic Stem Cell Transplants: Principles and Indications

Overview
Date 2018 Dec 29
PMID 30592675
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Haematopoietic stem cell transplantation was proposed as a treatment strategy just over 60 years ago. Owing to great advances in the field, haematopoietic stem cell transplantation has become an established method for the treatment of many haemato-oncological, immunological and hereditary conditions with the potential of cure. The number of haematopoietic stem cell transplants performed worldwide reached one million by 2012. This review provides an overview of autologous and allogeneic haematopoietic stem cell transplantation including disease indications, the individual steps of the procedure and outcome, and highlights achievements in the treatment of autoimmune diseases. Although autoimmune conditions account for only 1% of indications for autologous haematopoietic stem cell transplant, this is increasingly used to treat high-risk autoimmune diseases. Haematopoietic stem cell transplantation can induce long-term remission by resetting the immune system via eradication of autoreactive immune cells and the generation of a de novo self-tolerant immune system. Data seem most encouraging in multiple sclerosis and systemic sclerosis and it is likely that the number of procedures performed to treat these conditions will rise in the future.

Citing Articles

Targeted Cellular Treatment of Systemic Lupus Erythematosus.

Athanassiou P, Athanassiou L, Kostoglou-Athanassiou I, Shoenfeld Y Cells. 2025; 14(3).

PMID: 39937001 PMC: 11816398. DOI: 10.3390/cells14030210.


[Refractory or resistant cytomegalovirus infections after hematopoietic stem cell transplantation: diagnosis and management].

Zhang X, Jiang E Zhonghua Xue Ye Xue Za Zhi. 2025; 45(11):1058-1064.

PMID: 39746704 PMC: 11886676. DOI: 10.3760/cma.j.cn121090-20240615-00223.


Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience.

Arif S, Ali N, Shaikh U, Adil S, Jehanzeb H Int J Hematol Oncol Stem Cell Res. 2024; 18(4):344-357.

PMID: 39703474 PMC: 11652702. DOI: 10.18502/ijhoscr.v18i4.16759.


Work Participation of Hematological Cancer Survivors After Hematopoietic Cell Transplantation: A Scoping Review.

Bilodeau K, Vinette B, Gelinas-Gagne C, Torabi P, Hartono B, Desilets M J Occup Rehabil. 2024; .

PMID: 39607656 DOI: 10.1007/s10926-024-10257-0.


Knowledge, attitude, and perception of exercises among post-hematopoietic stem cell transplant patients: A cross-sectional study.

Han N, Wu C, Liu N, Deng Y, Zhang L, Zhu Y Medicine (Baltimore). 2024; 103(45):e40036.

PMID: 39533570 PMC: 11557101. DOI: 10.1097/MD.0000000000040036.